Another quarter, another industry snapshot. We sat down with experts at BPI West to discuss the current state of biomanufacturing. Our State of the Industry series began last year to allow reflection on quarterly trends within the bioprocess and manufacturing sector. Clearly the pandemic has driven much of the conversation, but in a sign of COVID’s decline this quarter’s panel was held not on Zoom, Teams, or Skype but in a real face-to-face setting: BPI West in San Diego. Our…
CDMO Catalent has picked up the UK taxpayer-funded Vaccine Manufacturing & Innovation Centre (VMIC) for an undisclosed fee. In early 2020 as the COVID-19 pandemic hit, the UK Government’s Vaccine Taskforce invested around £200 million ($270 million) into a facility aimed at addressing the country’s lack of vaccine manufacturing capacity. The 74,000 square-foot VMIC in Harwell, near Oxford – about 50 miles west of London – had been expected to offer up to 70 million doses of pandemic vaccine, deliverable…
The Novartis facility in North Carolina will begin shipping Zolgensma gene therapy doses immediately after receiving US FDA commercial licensure approval. The Swiss Big Pharma firm announced yesterday the US Food and Drug Administration (FDA) has granted approval to its multi-product gene therapy manufacturing facility in Durham, North Carolina. The 170,000 square-foot facility site will primarily be used to produce Zolgensma (onasemnogene abeparvovec. Novartis added Zolgensma to its pipeline through the $8.7 billion acquisition of AveXis in May 2018 and…